- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07942194
Prospective Multicentre Validation of a Landmark Machine Learning Model for ICU Mortality in Neurocritical Care (LANDMARK-ICU)
A Prospective Multicentre Observational Study Validating a Landmark-Based Machine Learning Model for Dynamic Prediction of Mortality in Patients Receiving Continuous Intracranial Pressure Monitoring
Mortality prediction in neurocritical care relies on scores computed at admission, which cannot update as the clinical course evolves. We previously developed a landmark-based machine learning model that converts hourly physiological data, including intracranial pressure, into an updating risk of death. The model was developed in a large public database and validated retrospectively in a second, independent one. This prospective multicentre study will test the model in consecutive patients at participating hospitals in Fujian Province, China. Physiological data will be collected as part of routine care. The model will generate risk estimates that are recorded for analysis but not shown to treating clinicians, and no treatment decision will be influenced by the study. The primary analysis will assess discrimination and calibration of the model for death during the intensive care stay. Secondary analyses will compare the model with severity scores in routine use and examine performance by aetiology.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
Model development used the Medical Information Mart for Intensive Care IV database and external validation used the eICU Collaborative Research Database. Both analyses were retrospective and are not part of this registration. This registration covers the prospective multicentre validation only. Inclusion requires age 18 years or older, continuous intracranial pressure monitoring for at least 24 hours, and a diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage. The model uses seven hourly physiological channels with observation masks and elapsed-time features. The primary endpoint is death during the intensive care stay; 28-day mortality, length of stay and Glasgow Outcome Scale at 6 months are secondary. The sample size of 100 patients follows the approved protocol, which assumed area under the curve 0.80 with alpha 0.05 and beta 0.20.
Тип исследования
Регистрация (Оцененный)
Контакты и местонахождение
Места учебы
-
-
Fujian
-
Fuzhou, Fujian, Китай
- Fujian Provincial Hospital
-
Fuzhou, Fujian, Китай
- First Affiliated Hospital of Fujian Medical University
-
Quanzhou, Fujian, Китай
- Hui'an County Hospital
-
Quanzhou, Fujian, Китай
- Second Affiliated Hospital of Fujian Medical University
-
Quanzhou, Fujian, Китай
- Shishi City Hospital
-
Zhangzhou, Fujian, Китай
- Zhangzhou Municipal Hospital
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Adults in intensive care units of participating hospitals who require continuous intracranial pressure monitoring after acute brain injury.
Описание
Inclusion Criteria:
- Age 18 years or older
- Continuous intracranial pressure monitoring for at least 24 hours
- Diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage
- Written informed consent from the patient or a legal representative
Exclusion Criteria:
- Incomplete or unusable intracranial pressure recordings
- Loss to follow-up or unavailable outcome information
- Pre-existing severe neurological disease that would confound assessment
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: PROSPECTIVE
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
|---|---|
|
Neurocritical care cohort
Consecutive patients receiving continuous intracranial pressure monitoring, contributing to the risk set at each landmark. |
Observational application of a fixed prediction model to hourly physiological data; no treatment is assigned or withheld. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 24-hour landmark
Временное ограничение: 24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
Discrimination of the locked landmark model, quantified as the area under the receiver operating characteristic curve, where 0.5 indicates no discrimination and 1.0 perfect discrimination. Death is ascertained from the medical record and the curve is estimated with a 95% confidence interval |
24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 48-hour and 72-hour landmarks
Временное ограничение: 48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
Same measurement as the primary outcome, estimated separately at the 48-hour and 72-hour landmarks with 95% confidence intervals |
48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
|
Calibration slope (dimensionless) of the landmark model at the 24-, 48- and 72-hour landmarks
Временное ограничение: 24, 48 and 72 hours after intensive care admission
|
Slope obtained by logistic regression of the observed outcome on the logit of the predicted risk; a value of 1 indicates perfect calibration, below 1 indicates over-fitting and above 1 under-fitting. |
24, 48 and 72 hours after intensive care admission
|
|
Brier score (range 0 to 1) of the landmark model at the 24-, 48- and 72-hour landmarks
Временное ограничение: 24, 48 and 72 hours after intensive care admission
|
Mean squared difference between predicted risk and observed outcome, where lower values indicate better overall performance. |
24, 48 and 72 hours after intensive care admission
|
|
Difference in area under the receiver operating characteristic curve (range -1 to 1) between the landmark model and the centre-recorded APACHE II score
Временное ограничение: 24, 48 and 72 hours after intensive care admission
|
Paired difference in discrimination, computed as model area under the curve minus APACHE II area under the curve on the same patients, with 95% confidence interval; negative values indicate the model discriminates worse than APACHE II |
24, 48 and 72 hours after intensive care admission
|
|
Net benefit (dimensionless) of the landmark model from decision-curve analysis at the 24-hour landmark
Временное ограничение: 24 hours after intensive care admission
|
Net benefit computed across threshold probabilities from 0.05 to 0.50, compared with the strategies of treating all patients and treating none |
24 hours after intensive care admission
|
|
Area under the receiver operating characteristic curve (range 0 to 1) by primary diagnosis at the 24-, 48- and 72-hour landmarks
Временное ограничение: 24, 48 and 72 hours after intensive care admission
|
Discrimination estimated separately for traumatic brain injury, aneurysmal subarachnoid haemorrhage and intracerebral haemorrhage, reported descriptively because stratum sizes are expected to be small |
24, 48 and 72 hours after intensive care admission
|
|
28-day all-cause mortality, as specified in the approved protocol
Временное ограничение: 28 days after intensive care admission
|
28 days after intensive care admission
|
|
|
Length of intensive care stay
Временное ограничение: From intensive care admission to intensive care unit discharge, up to 28 days
|
Duration of intensive care stay in days, right-censored at day 28 for patients still in intensive care |
From intensive care admission to intensive care unit discharge, up to 28 days
|
|
Glasgow Outcome Scale score (range 1 to 5, higher is better) at 6 months
Временное ограничение: 6 months after intensive care admission
|
Glasgow Outcome Scale, an ordinal scale from 1 (death) to 5 (good recovery), with higher scores indicating better outcome; assessed by telephone or outpatient follow-up |
6 months after intensive care admission
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Главный следователь: Han Chen, MD, Fujian Provincial Hospital
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Цереброваскулярные расстройства
- Заболевания головного мозга
- Заболевания центральной нервной системы
- Заболевания нервной системы
- Сосудистые заболевания
- Сердечно-сосудистые заболевания
- Раны и травмы
- Патологические процессы
- Атрибуты болезни
- Кровотечение
- Черепно-мозговая травма
- Травма, нервная система
- Внутричерепные кровоизлияния
- Травмы головного мозга
- Патологические состояния, признаки и симптомы
- Повреждения головного мозга, травматические
- Критических заболеваний
- Кровоизлияние в мозг
- Субарахноидальное кровоизлияние
- Внутричерепная гипертензия
Другие идентификационные номера исследования
- FJPH-ICP-01
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
De-identified individual participant data will not be shared publicly because small centre volumes could permit re-identification. The model specification, analysis code and summary results will be published.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .